Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer.

Breast disease Pub Date : 2022-01-01 DOI:10.3233/BD-210023

Sadaf Jafferbhoy, Manoj Gowda S, Kirti Katherine Kabeer, Zatinahhayu Mohd-Isa, Seema Salehi-Bird, Sekhar Marla, Sankaran Narayanan, Soni Soumian

{"title":"Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer.","authors":"Sadaf Jafferbhoy, Manoj Gowda S, Kirti Katherine Kabeer, Zatinahhayu Mohd-Isa, Seema Salehi-Bird, Sekhar Marla, Sankaran Narayanan, Soni Soumian","doi":"10.3233/BD-210023","DOIUrl":null,"url":null,"abstract":"Background and objectives: MRI is generally performed to assess response to Neo-adjuvant systemic therapy (NAST) in breast cancer.Objective: To assess role of MRI in determining the probability of having residual disease in patients undergoing NAST. We also evaluated synchronous cancers diagnosed following MRI.Methods: This is a retrospective study which included all patients who had pre-and post-NAST MRI between June 2014 and December 2019. Data on demographics, tumour characteristics and pathology were collected and analysed. Pre- and post-MRI probability were calculated and depicted on nomograms.Results: The study included 205 patients. Overall pre-MRI probability of having residual disease was 55% (OR:1.2). The post-MRI probability was 78% (95% CI 72-83%; OR:3.5) if MRI showed residual disease and 23% (95% CI 16-31%, OR:0.3) if imaging showed complete response. The absolute benefit was higher in TNBC and HR-HER2. Additional cancers were identified in 8.78% of patients.Conclusion: MRI is beneficial in evaluating response to NAST specifically in TNBC and HR-HER2 cancers. Pre- and post-MRI probabilities of residual disease depicted on nomograms are a useful tool for clinicians. MRI can potentially impact the treatment decisions by identification of synchronous cancers.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-210023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background and objectives: MRI is generally performed to assess response to Neo-adjuvant systemic therapy (NAST) in breast cancer.

Objective: To assess role of MRI in determining the probability of having residual disease in patients undergoing NAST. We also evaluated synchronous cancers diagnosed following MRI.

Methods: This is a retrospective study which included all patients who had pre-and post-NAST MRI between June 2014 and December 2019. Data on demographics, tumour characteristics and pathology were collected and analysed. Pre- and post-MRI probability were calculated and depicted on nomograms.

Results: The study included 205 patients. Overall pre-MRI probability of having residual disease was 55% (OR:1.2). The post-MRI probability was 78% (95% CI 72-83%; OR:3.5) if MRI showed residual disease and 23% (95% CI 16-31%, OR:0.3) if imaging showed complete response. The absolute benefit was higher in TNBC and HR-HER2. Additional cancers were identified in 8.78% of patients.

Conclusion: MRI is beneficial in evaluating response to NAST specifically in TNBC and HR-HER2 cancers. Pre- and post-MRI probabilities of residual disease depicted on nomograms are a useful tool for clinicians. MRI can potentially impact the treatment decisions by identification of synchronous cancers.

查看原文本刊更多论文

MRI在预测乳腺癌新辅助全身治疗(NAST)应答中的作用。

背景和目的:MRI通常用于评估乳腺癌患者对新辅助全身治疗(NAST)的反应。目的:探讨核磁共振成像(MRI)在确定NAST患者残留病变概率中的作用。我们也评估了MRI诊断的同步癌。方法:这是一项回顾性研究，纳入了2014年6月至2019年12月期间所有接受过nast MRI前后的患者。收集和分析了人口统计学、肿瘤特征和病理数据。计算了mri前后的概率并在图上进行了描述。结果:纳入205例患者。总体mri前病变残留概率为55% (OR:1.2)。mri后的概率为78% (95% CI 72-83%;如果MRI显示残留病变，OR为3.5)，如果影像学显示完全缓解，OR为23% (95% CI 16-31%， OR:0.3)。TNBC和HR-HER2的绝对获益更高。在8.78%的患者中发现了其他癌症。结论:MRI有助于评估TNBC和HR-HER2肿瘤对NAST的反应。造影图上描述的mri前和mri后残留疾病的概率是临床医生的有用工具。MRI可以通过识别同步性癌症来潜在地影响治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.

文献相关原料

公司名称	产品信息	采购帮参考价格